Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma

Chuan Cheng Wang, Jang Yang Chang, Tsang Wu Liu, Chin Yu Lin, Yu Chieh Yu, Ruey Long Hong

Research output: Contribution to journalArticlepeer-review

44 Citations (Scopus)

Abstract

Background. A phase II study was conducted to evaluate the safety and efficacy of a gemcitabine plus vinorelbine combination (GV) for patients with cisplatin-resistant nasopharyngeal carcinoma (NPC). Methods. Thirty-nine eligible patients received vinorelbine, 20 mg/m2, followed by gemcitabine, 1000 mg/m2, on days 1 and 8 of each 21-day cycle. Results. Grade 3/4 neutropenia and thrombocytopenia occurred in 44% and 18% of patients, respectively, but there was only one episode of febrile neutropenia. Nonhematologic toxicities were mild and did not lead to any treatment withdrawal. The overall response rate was 36% (95% confidence interval [Cl], 20% to 52%) in an intent-to-treat analysis, with one complete response (3%) and 13 partial responses (33%). The median response duration, progression-free survival, and overall survival were 5.1, 5.6, and 11.9 months, respectively. Conclusion. Given the moderately high activity and favorable toxicity profile, GV is a reasonable choice for patients with cisplatin-resistant NPC.

Original languageEnglish
Pages (from-to)74-80
Number of pages7
JournalHead and Neck
Volume28
Issue number1
DOIs
Publication statusPublished - 2006 Jan 1

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma'. Together they form a unique fingerprint.

Cite this